<DOC>
	<DOCNO>NCT02820558</DOCNO>
	<brief_summary>This study evaluate delivery substance P via celiac artery treatment recent onset type 1 diabetes .</brief_summary>
	<brief_title>Neuropeptide Therapy Recent Onset Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Substance P</mesh_term>
	<mesh_term>Neurokinin A</mesh_term>
	<criteria>Recent onset T1D ( CDA 2013 guideline : See link link section Age 1018 year Disease Duration 330 month Fasting CPeptide ( measure screening ) great equal 33 pmol/L Post honeymoon phase base follow criterion : History HbA1c value insulin requirement diagnosis indicate honeymoon period follow increased insulin requirement time recruitment &gt; 0.50 units/Kg together HbA1c value &gt; 7.2 % ; Patients diabetes duration &gt; 3 month never experience honeymoon period reflect consistent HbA1c value &gt; 7.2 % time diagnosis time recruitment use insulin dose &gt; 0.50 units/Kg . The presence one TRPV1 alleles similar find patient currently enrol TRPV1North American European Study . Stimulated CPeptide ( measure mixed meal tolerance Stage A Stage B sP trial ) â‰¥ 200 pmol/L less equal 1500 pmol/L . Patients known comorbidities , include ACEinhibitor treat hypertension well chromosomal abnormality , involve one organ system . Type 2 Diabetes Mellitus Patients known radiographic contrast allergy Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Neuropeptide</keyword>
	<keyword>Therapy</keyword>
	<keyword>Onset</keyword>
</DOC>